Ascendis Pharma As Stock Earnings Per Share
| ASND Stock | USD 136.00 0.32 0.23% |
Ascendis Pharma AS fundamentals help investors to digest information that contributes to Ascendis Pharma's financial success or failures. It also enables traders to predict the movement of Ascendis Stock. The fundamental analysis module provides a way to measure Ascendis Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ascendis Pharma stock.
Ascendis | Earnings Per Share |
Ascendis Pharma AS Company Earnings Per Share Analysis
Ascendis Pharma's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Ascendis Pharma Earnings Per Share | (7.82) X |
Most of Ascendis Pharma's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ascendis Pharma AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Ascendis Earnings Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Ascendis Pharma is extremely important. It helps to project a fair market value of Ascendis Stock properly, considering its historical fundamentals such as Earnings Per Share. Since Ascendis Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ascendis Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ascendis Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
Ascendis Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
According to the company disclosure, Ascendis Pharma AS has an Earnings Per Share of -7.82 times. This is 193.43% lower than that of the Biotechnology sector and 63.26% higher than that of the Health Care industry. The earnings per share for all United States stocks is notably higher than that of the company.
Ascendis Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ascendis Pharma's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ascendis Pharma could also be used in its relative valuation, which is a method of valuing Ascendis Pharma by comparing valuation metrics of similar companies.Ascendis Pharma is currently under evaluation in earnings per share category among its peers.
Ascendis Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Ascendis Pharma from analyzing Ascendis Pharma's financial statements. These drivers represent accounts that assess Ascendis Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Ascendis Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 5.8B | 6.9B | 6.5B | 6.4B | 6.4B | 6.7B | |
| Enterprise Value | 5.2B | 6.4B | 6.1B | 6.5B | 6.7B | 7.0B |
Ascendis Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ascendis Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ascendis Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Ascendis Fundamentals
| Return On Equity | -8.18 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (1.54) % | ||||
| Operating Margin | (3.70) % | ||||
| Current Valuation | 8.32 B | ||||
| Shares Outstanding | 59.76 M | ||||
| Shares Owned By Insiders | 0.73 % | ||||
| Shares Owned By Institutions | 99.27 % | ||||
| Number Of Shares Shorted | 3.57 M | ||||
| Price To Earning | (9.10) X | ||||
| Price To Book | 14.55 X | ||||
| Price To Sales | 25.65 X | ||||
| Revenue | 266.72 M | ||||
| Gross Profit | 39.04 M | ||||
| EBITDA | (411.17 M) | ||||
| Net Income | (481.45 M) | ||||
| Cash And Equivalents | 955.15 M | ||||
| Cash Per Share | 17.11 X | ||||
| Total Debt | 644.26 M | ||||
| Debt To Equity | 0.84 % | ||||
| Current Ratio | 9.66 X | ||||
| Book Value Per Share | (2.57) X | ||||
| Cash Flow From Operations | (467.36 M) | ||||
| Short Ratio | 8.50 X | ||||
| Earnings Per Share | (7.82) X | ||||
| Price To Earnings To Growth | 10.25 X | ||||
| Target Price | 181.98 | ||||
| Number Of Employees | 879 | ||||
| Beta | 0.65 | ||||
| Market Capitalization | 8.15 B | ||||
| Total Asset | 825.59 M | ||||
| Retained Earnings | (2.28 B) | ||||
| Working Capital | 505.38 M | ||||
| Current Asset | 125.65 M | ||||
| Current Liabilities | 11.45 M | ||||
| Net Asset | 825.59 M |
About Ascendis Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ascendis Pharma AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascendis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascendis Pharma AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:Check out Ascendis Pharma Piotroski F Score and Ascendis Pharma Altman Z Score analysis. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.82) | Revenue Per Share 5.595 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (8.18) |
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.